Mr. Andre Larente reports

Diagnos IS FILING FOR THE SAUDI FDA AUTHORIZATION OF ITS CARA SYSTEM, AN AI ASSISTED MEDICAL DEVICE

Diagnos Inc. is officially filing for Saudi Food and Drug Administration (Saudi FDA) authorization of its CARA (computer-assisted retina analysis) system, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory process, Diagnos is working with Kanhoor Medical Company, the company's authorized representative for the Saudi Arabia market.

The CARA system is designed to assist front-line health care professionals in processing, analyzing and annotating fundus images for the early detection of diabetic retinopathy, age-related macular degeneration and hypertensive retinopathy. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

With this new filing, the company will upgrade its present medical device marketing device authorization to include the early detection of diabetic retinopathy, age-related macular degeneration and, at a later date, hypertensive retinopathy.

"Diagnos is committed to revolutionizing eye health through artificial intelligence technologies," said Andre Larente, chief executive officer of Diagnos. "Our expertise in artificial intelligence driven Diagnostics is helping to improve patient outcomes worldwide. As per the latest IDF (International Diabetic Federation), the prevalence of diabetes in adults was at 17.7 per cent in Saudi Arabia, or more than four million patients at risk of some level of vision loss. Our solution can help triage this population efficiently to prevent permanent damage on vision caused by the complication of diabetes. Our local partner, Kanhoor Medical is helping with government-related business initiatives, marking an exciting phase of growth for Diagnos."

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.